This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ping-I (William) Hsu, M.D., Kaohsiung Veterans General Hospital.
ClinicalTrials.gov Identifier:
NCT01138969
First received: June 7, 2010
Last updated: September 6, 2015
Last verified: September 2015
June 7, 2010
September 6, 2015
August 2008
December 2012   (Final data collection date for primary outcome measure)
Recurrent Peptic Ulcer [ Time Frame: 6 months ]
Number of participants with recurrent peptic ulcer within 6 months
Rate of Recurrent Peptic Ulcer [ Time Frame: 6 months ]
rate of recurrent peptic ulcer within 6 months
Complete list of historical versions of study NCT01138969 on ClinicalTrials.gov Archive Site
Peptic Ulcer Bleeding [ Time Frame: 6 months ]
participants with peptic ulcer bleeding within 6 months
Rate of Peptic Ulcer Bleeding [ Time Frame: 6 months ]
rate of peptic ulcer bleeding within 6 months
Not Provided
Not Provided
 
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
The aim of the prospective, randomized study is to investigate the efficacy of PPI in prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be compared.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Peptic Ulcer
Drug: esomeprazole
esomeprazole 20 mg qd for 6 months
Other Name: plavix
  • Active Comparator: Esomeprazole plus clopidogrel group
    esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
    Intervention: Drug: esomeprazole
  • No Intervention: Clopidogrel group
    clopidogrel 75 mg qd for 6 months
Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011 Mar;140(3):791-8. doi: 10.1053/j.gastro.2010.11.056. Epub 2010 Dec 7. Erratum in: Gastroenterology. 2011 Aug;141(2):778.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
165
December 2012
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months.

Exclusion Criteria:

  • 1.serious disease 2.refuse informed consent
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT01138969
VGHKS98-CT6-12
Yes
Not Provided
Not Provided
Not Provided
Ping-I (William) Hsu, M.D., Kaohsiung Veterans General Hospital.
Kaohsiung Veterans General Hospital.
Not Provided
Study Chair: Kwok-Hung Lai, MD Kaohsiung Veterans General Hospital.
Kaohsiung Veterans General Hospital.
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP